Wolverine Trading’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $666M | Buy |
916,400
+106,800
| +13% | +$79.5M | 0.48% | 39 |
|
|
2025
Q2 | $628M | Buy |
809,600
+111,000
| +16% | +$86.3M | 0.63% | 27 |
|
|
2025
Q1 | $575M | Buy |
698,600
+243,500
| +54% | +$203M | 0.67% | 27 |
|
|
2024
Q4 | $352M | Sell |
455,100
-35,300
| -7% | -$29.2M | 0.33% | 40 |
|
|
2024
Q3 | $430M | Buy |
490,400
+151,900
| +45% | +$137M | 0.45% | 32 |
|
|
2024
Q2 | $306M | Buy |
338,500
+11,700
| +4% | +$9.36M | 0.32% | 46 |
|
|
2024
Q1 | $254M | Sell |
326,800
-32,800
| -9% | -$23.3M | 0.26% | 45 |
|
|
2023
Q4 | $210M | Buy |
359,600
+29,000
| +9% | +$16.9M | 0.22% | 51 |
|
|
2023
Q3 | $178M | Buy |
330,600
+24,700
| +8% | +$12.7M | 0.18% | 51 |
|
|
2023
Q2 | $142M | Buy |
305,900
+23,200
| +8% | +$9.73M | 0.17% | 58 |
|
|
2023
Q1 | $96.3M | Buy |
282,700
+79,300
| +39% | +$26.7M | 0.15% | 70 |
|
|
2022
Q4 | $74.4M | Buy |
+203,400
| New | +$72.1M | 0.11% | 129 |
|
|
2022
Q3 | – | Sell |
-137,900
| Closed | -$44.5M | – | 5005 |
|
|
2022
Q2 | $44.5M | Buy |
137,900
+3,700
| +3% | +$1.11M | 0.07% | 139 |
|
|
2022
Q1 | $38.9M | Buy |
134,200
+16,800
| +14% | +$4.32M | 0.05% | 248 |
|
|
2021
Q4 | $32.5M | Buy |
117,400
+57,800
| +97% | +$14.7M | 0.04% | 332 |
|
|
2021
Q3 | $13.7M | Sell |
59,600
-359,000
| -86% | -$88.6M | 0.02% | 661 |
|
|
2021
Q2 | $96M | Buy |
418,600
+305,000
| +268% | +$61.3M | 0.15% | 84 |
|
|
2021
Q1 | $21.1M | Buy |
113,600
+39,900
| +54% | +$7.8M | 0.03% | 378 |
|
|
2020
Q4 | $12.3M | Buy |
73,700
+6,300
| +9% | +$941K | 0.02% | 593 |
|
|
2020
Q3 | $9.86M | Sell |
67,400
-37,400
| -36% | -$5.79M | 0.02% | 540 |
|
|
2020
Q2 | $17.1M | Sell |
104,800
-70,300
| -40% | -$10.8M | 0.05% | 289 |
|
|
2020
Q1 | $24.2M | Sell |
175,100
-30,300
| -15% | -$4.16M | 0.07% | 179 |
|
|
2019
Q4 | $27M | Buy |
205,400
+7,000
| +4% | +$811K | 0.07% | 256 |
|
|
2019
Q3 | $22.3M | Sell |
198,400
-23,800
| -11% | -$2.65M | 0.06% | 246 |
|
|
2019
Q2 | $24.6M | Sell |
222,200
-155,700
| -41% | -$18.3M | 0.07% | 231 |
|
|
2019
Q1 | $49M | Buy |
377,900
+130,000
| +52% | +$15.8M | 0.14% | 89 |
|
|
2018
Q4 | $28.3M | Buy |
247,900
+65,400
| +36% | +$7.31M | 0.08% | 171 |
|
|
2018
Q3 | $19.6M | Buy |
182,500
+29,600
| +19% | +$2.96M | 0.04% | 307 |
|
|
2018
Q2 | $11.8M | Hold |
152,900
| – | – | 0.03% | 429 |
|
|
2018
Q1 | $11.8M | Buy |
152,900
+44,000
| +40% | +$3.54M | 0.03% | 429 |
|
|
2017
Q4 | $9.2M | Buy |
+108,900
| New | +$9.27M | 0.03% | 542 |
|
|
2017
Q3 | – | Sell |
-141,600
| Closed | -$11.7M | – | 4758 |
|
|
2017
Q2 | $11.7M | Buy |
141,600
+17,100
| +14% | +$1.4M | 0.05% | 327 |
|
|
2017
Q1 | $10.6M | Sell |
124,500
-93,200
| -43% | -$7.46M | 0.06% | 352 |
|
|
2016
Q4 | $16M | Buy |
217,700
+29,000
| +15% | +$2.16M | 0.08% | 262 |
|
|
2016
Q3 | $15M | Buy |
188,700
+115,700
| +158% | +$9.26M | 0.07% | 314 |
|
|
2016
Q2 | $5.71M | Buy |
+73,000
| New | +$5.5M | 0.03% | 557 |
|
Other funds holding LLY
Wolverine Trading's LLY Position: Q3 2025 in Review
Wolverine Trading reduced its Eli Lilly (LLY) stake by 51% in Q3 2025, selling an estimated $15.2M and leaving 19,630 shares worth $14.3M. The position accounts for 0.01% of the portfolio, ranked #750.
Wolverine Trading first reported a position in LLY in Q2 2016 and has held it in 35 quarters since. The position peaked at $147M in Q2 2024. 3,897 funds tracked by Wall St. Rank hold LLY as of Q3 2025.
- Wolverine Trading held 19,630 shares of Eli Lilly worth $14.3M as of Q3 2025.
- Wolverine Trading sold 20,386 Eli Lilly shares in Q3 2025, an estimated $15.2M.
- Eli Lilly made up 0.01% of Wolverine Trading's portfolio in Q3 2025, its #750 holding.
- Wolverine Trading first reported a position in Eli Lilly in Q2 2016 and has held it in 35 quarters since.
- Wolverine Trading's Eli Lilly position peaked at $147M in Q2 2024.
- 3,897 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2025.
Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.